Life Sciences

Delinking the cost of R&D from the final prices of medicines and making governments the funders and planners of drug development would be rife with problems.
Life Sciences
Check a box to narrow search for individual content items that cover numerous issues.
March 9, 2015
To ensure the Trans-Pacific Partnership (TPP) Agreement creates a framework in which life sciences innovation flourishes throughout the TPP region, it needs to include 12 years of data protection for novel biologic drugs.
February 26, 2015
The National Institutes of Health needs greater resources and more funding stability.
February 17, 2015
IP protection is essential to future medical innovation.
January 8, 2015
Policymakers should be wary of adverse side effects when promoting competition for short-term consumer welfare.
January 7, 2015
New evidence demonstrates that IPRs have not decreased access to medicines.
April 10, 2014
To remain a leader in medical innovation, U.S. must strengthen research and IP.
March 17, 2014
What if innovation in life sciences stopped? A new study on Swedish healthcare provides insight.
March 14, 2014
The President's FY 2015 budget should do more to promote the innovation capacity and competitiveness of U.S. life sciences industries.
December 1, 2013
The TPP will only be worth it if it concludes with an innovation-maximizing trade agreement that sets the standard for future trade deals for the U.S.
July 8, 2013
Better use of data analytics can help us make better predictions and fewer errors.

Pages